替雷利珠联合化疗治疗非小细胞肺癌手术患者的效果  

Efficacy of tirilizumab combined with chemotherapy in patients undergoing surgery for non-small cell lung cancer

作　　者：高薇薇 邵春艳 姜洁 王欢 张磊[1] Gao Wei-wei;Shao Chun-yan;Jiang Jie;Wang Huan;Zhang Lei(Department of Oncology,Suining County People’s Hospital,Suining 221200,China)

机构地区：[1]睢宁县人民医院肿瘤科,睢宁221200

出　　处：《中国药物应用与监测》2024年第2期106-109,共4页Chinese Journal of Drug Application and Monitoring

基　　金：徐州市卫生健康委员会项目(XHKYSL20210266)。

摘　　要：目的评价替雷利珠单抗在含铂双药化疗治疗的非小细胞肺癌手术患者中的应用效果。方法选取2022年1月—2023年12月收治的100例拟行手术治疗的非小细胞肺癌患者,根据随机数字表法将其分成两组。对照组50例患者在术前给予含铂双药治疗,观察组50例患者在其治疗基础上加用替雷利珠单抗治疗。比较两组临床疗效、无事件及无疾病生存率、生活质量改善情况、不良反应。结果观察组临床疗效(完全缓解率:20.00%vs.10.00%)及病理评估(主要病理学缓解率:46.00%vs.20.00%)优于对照组(Z=3.484,P<0.001;χ^(2)=7.664,P=0.006);Kaplan-Meier生存分析显示,观察组无事件生存率(84.00%vs.60.00%)及无疾病生存率(78.00%vs.60.00%)均高于对照组(χ^(2)=4.298,P=0.038;χ^(2)=4.783,P=0.029);在生活质量改善率方面,观察组(64.00%)较对照组高(42.00%),差异有统计学意义(χ^(2)=4.857,P=0.028);两组不良反应发生率(18.00%vs.22.00%)比较,差异无统计学意义(χ^(2)=0.250,P=0.617)。结论在含铂双药化疗治疗非小细胞肺癌手术患者中的实施替雷利珠单抗治疗可提高治疗效果,促进生活质量改善,且不会增加不良反应发生风险。Objective To evaluate the efficacy of tirilizumab in patients undergoing surgery for non-small cell lung cancer treated with platinum-containing two-agent chemotherapy.Methods One hundred patients with non-small cell lung cancer who underwent surgical treatment from January 2022 to December 2023 were selected and randomly divided into two groups according to the random number table method.Fifty patients in the control group were treated with platinum-based doublet chemotherapy before surgery,while fifty patients in the observation one with tislelizumab in addition to the control group treatment.The clinical efficacy,event-free survival,disease-free survival,quality of life improvement,and toxic and side effects were compared between the two groups.Results The clinical efficacy(complete remission rate:20.00%vs.10.00%)and pathological evaluation(major pathological response rate:46.00%vs.20.00%)of the observation group were better than those of the control(Z=3.484,P<0.001;χ^(2)=7.664,P=0.006).Kaplan-Meier survival analysis showed that the event-free survival rate(84.00%vs.60.00%)and disease-free survival rate(78.00%vs.60.00%)in the observation group were higher than those in the control(χ^(2)=4.298,P=0.038;χ^(2)=4.783,P=0.029).In terms of quality of life improvement rate,the observation group(64.00%)was higher than the control(42.00%),and the difference was statistically significant(χ^(2)=4.857,P=0.028).There was no statistically significant difference in the incidence of toxic and side effects between the two groups(18.00%vs.22.00%)(χ^(2)=0.250,P=0.617).Conclusion The implementation of tirilizumab in patients undergoing surgery for NSCLC treated with platinum-containing dual-agent chemotherapy can improve the therapeutic efficacy,promote the improvement of the quality of life but does not increase the risk of the occurrence of toxic side effects in patients.

关 键 词：非小细胞肺癌 替雷利珠单抗 含铂双药 临床疗效 不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R969[医药卫生—临床医学]